Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Change in Accured Expenses (2016 - 2025)

Corbus Pharmaceuticals Holdings has reported Change in Accured Expenses over the past 9 years, most recently at $3.5 million for Q4 2023.

  • For Q4 2023, Change in Accured Expenses rose 198.98% year-over-year to $3.5 million; the TTM value through Dec 2023 reached $5.0 million, up 222.88%, while the annual FY2024 figure was -$5.6 million, 211.53% down from the prior year.
  • Change in Accured Expenses for Q4 2023 was $3.5 million at Corbus Pharmaceuticals Holdings, up from $1.1 million in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $5.6 million in Q1 2019 and troughed at -$6.6 million in Q4 2020.
  • A 5-year average of $58966.9 and a median of $283160.0 in 2020 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: soared 6150.57% in 2019 and later crashed 607.57% in 2020.
  • Year by year, Change in Accured Expenses stood at -$931024.0 in 2019, then crashed by 607.57% to -$6.6 million in 2020, then skyrocketed by 46.49% to -$3.5 million in 2021, then soared by 133.06% to $1.2 million in 2022, then surged by 198.98% to $3.5 million in 2023.
  • Business Quant data shows Change in Accured Expenses for CRBP at $3.5 million in Q4 2023, $1.1 million in Q3 2023, and -$49050.0 in Q2 2023.